Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients

被引：3

作者：

Trevisan, B. ^{[1
]}

Pepe, F. F. ^{[1
]}

Vallini, I. ^{[2
]}

Montagna, E. ^{[3
]}

Amoroso, D. ^{[4
]}

Berardi, R. ^{[5
]}

Butera, A. ^{[6
]}

Cagossi, K. ^{[7
]}

Cavanna, L. ^{[8
]}

Ciccarese, M. ^{[9
]}

Cinieri, S. ^{[10
]}

Cretella, E. ^{[11
]}

De Conciliis, E. ^{[12
]}

Febbraro, A. ^{[13
]}

Ferrau, F. ^{[14
]}

Ferzi, A. ^{[15
]}

Baldelli, A. ^{[16
]}

Fontana, A. ^{[17
]}

Gambaro, A. R. ^{[18
]}

Garrone, O. ^{[19
]}

Gebbia, V. ^{[20
]}

Generali, D. ^{[21
]}

Gianni, L. ^{[22
]}

Giovanardi, F. ^{[23
]}

Grassadonia, A. ^{[24
]}

Leonardi, V. ^{[25
]}

Sarti, S. ^{[26
]}

Musolino, A. ^{[27
]}

Nicolini, M. ^{[22
]}

Putzu, C. ^{[28
]}

Riccardi, F. ^{[29
]}

Santini, D. ^{[30
]}

Sarobba, M. G. ^{[31
]}

Schintu, M. G. ^{[32
]}

Scognamiglio, G. ^{[33
]}

Spadaro, P. ^{[34
]}

Taverniti, C. ^{[35
]}

Toniolo, D. ^{[36
]}

Tralongo, P. ^{[37
]}

Turletti, A. ^{[38
]}

Valenza, R. ^{[39
]}

Valerio, M. R. ^{[40
]}

Vici, P. ^{[41
]}

Clivio, L. ^{[42
]}

Torri, V. ^{[42
]}

Cazzaniga, M. E. ^{[1
]}

机构：

[1] Azienda Osped San Gerardo, Monza, Italy

[2] Osped Circolo & Fdn Macchi, Varese, Italy

[3] European Inst Oncol, Milan, Italy

[4] Osped Versilia, Camaiore, Italy

[5] Azienda Osped Univ Osped Riuniti, Torrette, Italy

[6] Nuovo Osped San Giovanni Dio, Florence, Italy

[7] Osped Ramazzini, Carpi, Italy

[8] Azienda Osped Piacenza, Piacenza, Italy

[9] Osped Vito Fazzi, Lecce, Italy

[10] Osped A Perrino, Brindisi, Italy

[11] Osped Bolzano, Bolzano, Italy

[12] ASL Asti, Asti, Italy

[13] Osped S Cuore Gesu Fatebenefratelli, Benevento, Italy

[14] Osped San Vincenzo, Taormina, Italy

[15] Azienda Osped Osped Civile Legnano, Magenta, Italy

[16] Osped San Salvatore, Coppito, Italy

[17] Azienda Osped Univ Pisana, Pisa, Italy

[18] ASST Fatebenefratelli Sacco, Milan, Italy

[19] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[20] Osped La Maddalena, Palermo, Italy

[21] Ist Ospitalieri Cremona, Cremona, Italy

[22] Osped Infermi, Rimini, Italy

[23] AUSL Romagna, Emilia Romagna, Italy

[24] Osped SS Annunziata, Taranto, Italy

[25] Osped Civ, Palermo, Italy

[26] IRCCS Ist Sci Romagnolo Studio Cura Tumori, Meldola, Italy

[27] Osped Parma, Parma, Italy

[28] Azienda Osped Univ, Sassari, Italy

[29] Osped Antonio Cardarelli, Naples, Italy

[30] Univ Campus Biomed, Rome, Italy

[31] Osped San Francesco, Nuoro, Italy

[32] Osped Giovanni Paolo II, Lecce, Italy

[33] Osped Valduce, Como, Italy

[34] Casa Cura Villa Salus Messina, Messina, Italy

[35] Osped Molinette, Turin, Italy

[36] Osped Circolo, Rho, Italy

[37] Osped Umberto I, Rome, Italy

[38] Osped Martini, Turin, Italy

[39] PO Vittorio Emanuele, Gela, Italy

[40] AOU Policlin Paolo Giaccone, Palermo, Italy

[41] INT Regina Elena, Rome, Italy

[42] IRCCS Mario Negri Inst Pharmacol Res, Milan, Italy

来源：

SCIENTIFIC REPORTS | 2023年 / 13卷 / 01期

关键词：

PHASE-II TRIAL; 1ST-LINE TREATMENT; INTERNATIONAL SOCIETY; ORAL VINORELBINE; CAPECITABINE; MANAGEMENT; RECOMMENDATIONS; ANGIOGENESIS; PACLITAXEL; WOMEN;

D O I：

10.1038/s41598-023-39386-x

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and frequent administration of chemotherapy at a lower dose and so whit less toxicity. Thus, this strategy could be attractive for elderly MBC patients. Aim of this analysis is to provide insights into mCHT's activity in a real-life setting of elderly MBC patients. Data of patients & GE; 75 years old included in VICTOR-6 study were analyzed. VICTOR-6 is a multicentre, Italian, retrospective study, which collected data on mCHT in MBC patients treated between 2011 and 2016. A total of 112 patients were included. At the beginning of mCHT, median age was 81 years (75-98) and in 33% of the patients mCHT was the first line choice. Overall Response Rate (ORR) and Disease Control Rate (DCR) were 27.9% and 79.3%, respectively. Median PFS ranged between 7.6 and 9.1 months, OS between 14.1 and 18.5 months. The most relevant toxicity was the hematological one (24.1%); severe toxicity (grade 3-4) ranged from 0.9% for skin toxicity up to 8% for hematologic one. This is a large study about mCHT in elderly MBC patients, providing insights to be further investigated in this subgroup of frail patients.

引用

页数：9

共 50 条

[1] Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
Cazzaniga, M. E.
Pinotti, G.
Montagna, E.
Amoroso, D.
Berardi, R.
Butera, A.
Cagossi, K.
Cavanna, L.
Ciccarese, M.
Cinieri, S.
Cretella, E.
De Conciliis, E.
Febbraro, A.
Ferrau, F.
Ferzi, A.
Fiorentini, G.
Fontana, A.
Gambaro, A. R.
Garrone, O.
Gebbia, V
Generali, D.
Gianni, L.
Giovanardi, F.
Grassadonia, A.
Leonardi, V
Marchetti, P.
Melegari, E.
Musolino, A.
Nicolini, M.
Putzu, C.
Riccardi, F.
Santini, D.
Saracchini, S.
Sarobba, M. G.
Schintu, M. G.
Scognamiglio, G.
Spadaro, P.
Taverniti, C.
Toniolo, D.
Tralongo, P.
Turletti, A.
Valenza, R.
Valerio, M. R.
Vici, P.
Clivio, L.
Torri, V
Cicchiello, F.
Riva, F.
Vallini, I
Mazza, M.
BREAST, 2019, 48 : 7 - 16
[2] Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
M. E. Cazzaniga
I. Vallini
E. Montagna
D. Amoroso
R. Berardi
A. Butera
K. Cagossi
L. Cavanna
M. Ciccarese
S. Cinieri
E. Cretella
E. De Conciliis
A. Febbraro
F. Ferraù
A. Ferzi
A. Baldelli
A. Fontana
A. R. Gambaro
O. Garrone
V. Gebbia
D. Generali
L. Gianni
F. Giovanardi
A. Grassadonia
V. Leonardi
P. Marchetti
S. Sarti
A. Musolino
M. Nicolini
C. Putzu
F. Riccardi
D. Santini
S. Saracchini
M. G. Sarobba
M. G. Schintu
G. Scognamiglio
P. Spadaro
C. Taverniti
D. Toniolo
P. Tralongo
A. Turletti
R. Valenza
M. R. Valerio
P. Vici
P. Di Mauro
V. Cogliati
S. Capici
L. Clivio
V. Torri
Breast Cancer Research and Treatment, 2021, 190 : 415 - 424
[3] Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
Cazzaniga, E.
Vallini, I
Montagna, E.
Amoroso, D.
Berardi, R.
Butera, A.
Cagossi, K.
Cavanna, L.
Ciccarese, M.
Cinieri, S.
Cretella, E.
De Conciliis, E.
Febbraro, A.
Ferrau, F.
Ferzi, A.
Baldelli, A.
Fontana, A.
Gambaro, A. R.
Garrone, O.
Gebbia, V
Generali, D.
Gianni, L.
Giovanardi, F.
Grassadonia, A.
Leonardi, V
Marchetti, P.
Sarti, S.
Musolino, A.
Nicolini, M.
Putzu, C.
Riccardi, F.
Santini, D.
Saracchini, S.
Sarobba, M. G.
Schintu, M. G.
Scognamiglio, G.
Spadaro, P.
Taverniti, C.
Toniolo, D.
Tralongo, P.
Turletti, A.
Valenza, R.
Valerio, M. R.
Vici, P.
Di Mauro, P.
Cogliati, V
Capici, S.
Clivio, L.
Torri, V
BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (03) : 415 - 424
[4] Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study
Del Prete, Salvatore
Cennamo, Gregorio
Leo, Luigi
Montella, Liliana
Vincenzi, Bruno
Biglietto, Maria
Andreozzi, Francesca
Prudente, Antonella
Iodice, Patrizia
Savastano, Clementina
Nappi, Anna
Montesarchio, Vincenzo
Addeo, Raffaele
FUTURE ONCOLOGY, 2017, 13 (05) : 415 - 423
[5] Geriatric Assessment Implementation before Chemotherapy in MEtastatic Prostate Cancer, Results from the Real-Life Study GAMERS
Gluszak, Cassandre
Campion, Loic
Seegers, Valerie
Cojocarasu, Oana
Commer, Jean-Marie
Priou, Frank
Rolland, Frederic
Terret, Catherine
Abadie-Lacourtoisie, Sophie
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (04)
[6] Final Results of an International Retrospective Observational Study in Patients with Advanced Breast Cancer Treated with Oral Vinorelbine-based Chemotherapy
Garcia Palomo, Andres
Glogowska, Iwona
Sommer, Harald
Malamos, Nikolaos
Kilar, Ewa
Lopez Vega, Jose M.
Torrecillas, Laura
Delozier, Thierry
Ettl, Johannes
Finek, Jindrich
ANTICANCER RESEARCH, 2012, 32 (10) : 4539 - 4545
[7] Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study
Cazzaniga, Marina E.
Torri, Valter
Riva, Francesca
Porcu, Luca
Cicchiello, Federica
Capici, Serena
Cortinovis, Diego
Digiacomo, Nunzio
Bidoli, Paolo
TUMORI JOURNAL, 2017, 103 (01): : E4 - E8
[8] Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting
Gamucci, Teresa
Pizzuti, Laura
Sperduti, Isabella
Mentuccia, Lucia
Vaccaro, Angela
Moscetti, Luca
Marchetti, Paolo
Carbognin, Luisa
Michelotti, Andrea
Iezzi, Laura
Cassano, Alessandra
Grassadonia, Antonino
Astone, Antonio
Botticelli, Andrea
Magnolfi, Emanuela
Di Lauro, Luigi
Sergi, Domenico
Fuso, Paola
Tinari, Nicola
Barba, Maddalena
Maugeri-Sacca, Marcello
Landucci, Elisabetta
Conti, Francesca
Sanguineti, Giuseppe
De Tursi, Michele
Iafrate, Gianni
Giordano, Antonio
Ciliberto, Gennaro
Natoli, Clara
Vici, Patrizia
JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (03) : 2313 - 2323
[9] Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program
Bertho, Marion
Fraisse, Julien
Patsouris, Anne
Cottu, Paul
Arnedos, Monica
Perol, David
Jaffre, Anne
Goncalves, Anthony
Lebitasy, Marie-Paule
D'Hondt, Veronique
Dalenc, Florence
Ferrero, Jean-Marc
Levy, Christelle
Dabakuyo, Sandrine
Rouzier, Roman
Penault-Llorca, Frederique
Uwer, Lionel
Eymard, Jean-Christophe
Breton, Mathias
Chevrot, Michael
Thureau, Sebastien
Petit, Thierry
Simon, Gaetane
Frenel, Jean-Sebastien
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[10] Real-life clinical benefit of oral metronomic cyclophosphamide administration in elderly and heavily pretreated epithelial ovarian cancer patients
Attianese, Daniela
Massobrio, Roberta
Giorgi, Margherita
Villa, Michela
Fuso, Luca
Badellino, Enrico
Bellero, Marco
Ferrero, Annamaria
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2024, 310 (04) : 2183 - 2190

← 1 2 3 4 5 →